Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, September 16, 2025

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 25 million to Basilea to continue to advance the development of Basilea’s novel antifungals fosmanogepix and BAL2062. This additional funding follows the achievement of a prespecified enrollment milestone in the fosmanogepix phase 3 study in candidemia/invasive candidiasis within the “Other Transaction Agreement” (OTA, agreement number 75A50124C00033), which allows for potential total funding of up to approximately USD 268 million to develop antifungal and antibacterial assets.

David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. These compounds, with novel mechanisms of action, promise new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening invasive fungal infections. There continues to be a high medical need for new innovative antifungal treatments.”

He added: “This third tranche of funding within the BARDA OTA will support our two ongoing phase 3 studies with fosmanogepix in yeast infections and in mold infections. It also provides further funding for the phase 2 development of BAL2062 in mold infections.”

The USD 25 million is in addition to the USD 68 million already committed by BARDA since the signing of the OTA in September 2024. BARDA’s financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities.

Full PR available here